TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2932330

Group type: EXPERIMENTAL
Intervention: Paraspinal EMG biofeedback
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 66

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 66
Study: 31886682

Group type: EXPERIMENTAL
Intervention: Early substance involvement (heavy drinking, marijuana use, daily smoking, and other illicit drug use)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early smoking (cigarettes)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonmarijuana illicit drugs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Substance experimentation prevention efforts
Number of subjects: 0
Study: 29334309

Group type: EXPERIMENTAL
Intervention: Resisted sprint training (RST)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Unresisted sprint training (UR)
Number of subjects: 18
Study: 28388963

Group type: EXPERIMENTAL
Intervention: Minimally invasive distal pancreatectomy (MIDP)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Open distal pancreatectomy (ODP)
Number of subjects: 102
Study: 25920290

Group type: EXPERIMENTAL
Intervention: BF + PFMT (biofeedback + pelvic floor muscle training)
Number of subjects: 61

Group type: COMPARATOR
Intervention: PFMT (pelvic floor muscle training)
Number of subjects: 61
Study: 23819423

Group type: EXPERIMENTAL
Intervention: Fluconazole 37.5 mg, Tinidazole 500 mg, Azithromycin 250 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Fluconazole 37.5 mg, Tinidazole 500 mg, Clindamycin 312.5 mg
Number of subjects: 50
Study: 20171350

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 18655709

Group type: EXPERIMENTAL
Intervention: Interactive phone- and mail-based intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Seven day accelerometry data
Number of subjects: 0
Study: 16997112

Group type: COMPARATOR
Intervention: Mandibular block using 2.1 mL of 2% lidocaine with 1:100 000 epinephrine for the inferior alveolar nerve, lingual nerve, and/or buccal nerve.
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control group (contralateral tooth)
Number of subjects: 123
Study: 12544380

Group type: EXPERIMENTAL
Intervention: Lithium augmentation of nortriptyline
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo augmentation of nortriptyline
Number of subjects: 92
Study: 10967487

Group type: EXPERIMENTAL
Intervention: Lippia multiflora essential oil (20% v/v) applied for 5 consecutive days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Benzyl benzoate preparation (same concentration as Lippia oil)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lippia multiflora essential oil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lippia multiflora essential oil in an enclosed system
Number of subjects: 0
Study: 9100588

Group type: EXPERIMENTAL
Intervention: Low dose L (0.2 mg/kg)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: High dose L (0.75 mg/kg)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Low dose L (0.2 mg/kg) in fasted nonobese
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Low dose L (0.2 mg/kg) in fed nonobese
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Low dose L (0.2 mg/kg) in fasted obese
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 8308943

Group type: EXPERIMENTAL
Intervention: Cocaine abstinence treatment
Number of subjects: 19
Study: 3541882

Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 29207899

Group type: EXPERIMENTAL
Intervention: Mat Pilates (MP) with TheraBand®
Number of subjects: 26

Group type: COMPARATOR
Intervention: Calisthenics exercises (Control)
Number of subjects: 26
Study: 27591236

Group type: EXPERIMENTAL
Intervention: Curettage
Number of subjects: 59

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 59
Study: 25173541

Group type: EXPERIMENTAL
Intervention: Apixaban 5mg twice daily
Number of subjects: 1993

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 1993
Study: 22683675

Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine (TIV)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: TIV in both years
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: TIV in the first year
Number of subjects: 64
Study: 19473807

Group type: EXPERIMENTAL
Intervention: Porous tantalum acetabular component
Number of subjects: 17

Group type: COMPARATOR
Intervention: Titanium acetabular component
Number of subjects: 17
Study: 18951618

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 16826390

Group type: EXPERIMENTAL
Intervention: Deep sedation (continuous infusion of midazolam and fentanyl) without neuromuscular blockade
Number of subjects: 19

Group type: COMPARATOR
Intervention: Paralysis induced by cis‐atracurium
Number of subjects: 19
Study: 12641301

Group type: COMPARATOR
Intervention: Planned cesarean section
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Planned vaginal birth
Number of subjects: 0
Study: 10915751

Group type: EXPERIMENTAL
Intervention: Famciclovir 500 mg 3 times daily
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Famciclovir 1.5 g once daily
Number of subjects: 417

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 417
Study: 8936892

Group type: EXPERIMENTAL
Intervention: Combined pharmacologic and psychological intervention (Cl)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Pharmacologic only (PO)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Cross-sectional control (CC)
Number of subjects: 162
Study: 1558500

Group type: EXPERIMENTAL
Intervention: Delayed primary wound closure
Number of subjects: 63

Group type: COMPARATOR
Intervention: Immediate wound closure
Number of subjects: 63
Study: 3155644

Group type: EXPERIMENTAL
Intervention: Synthetic thymosin alpha-1
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: RT
Number of subjects: 62
Study: 31874879

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 49

Group type: COMPARATOR
Intervention: Pethidine
Number of subjects: 49
Study: 28429577

Group type: EXPERIMENTAL
Intervention: Commercial provider (Weight Watchers)
Number of subjects: 268

Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 268
Study: 26637570

Group type: EXPERIMENTAL
Intervention: CRSwNP
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: CRSnNP
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study: 24030130

Group type: EXPERIMENTAL
Intervention: TEAM intervention (6-month intervention with scheduled visits, Brief Medication Questionnaires, and toolkits)
Number of subjects: 576

Group type: COMPARATOR
Intervention: Control (patient information only)
Number of subjects: 576
Study: 21149662

Group type: EXPERIMENTAL
Intervention: Subcutaneous recombinant interleukin 2 (rIL‐2) at dose level 2 (6 × 10(6) U/m(2))
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Subcutaneous recombinant interleukin 2 (rIL‐2)
Number of subjects: 33
Study: 18638265

Group type: EXPERIMENTAL
Intervention: Low-frequency pulsed current (Dermapulse)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 16528696

Group type: EXPERIMENTAL
Intervention: Single media literacy lessons
Number of subjects: 237
Study: 12958617

Group type: EXPERIMENTAL
Intervention: Cerivastatin discontinuation
Number of subjects: 34

Group type: COMPARATOR
Intervention: Simvastatin treatment
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Simvastatin after 60 days of diet
Number of subjects: 34
Study: 10991852

Group type: EXPERIMENTAL
Intervention: Fosfomycin 4 g
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Fosfomycin 8 g
Number of subjects: 6
Study: 8827693

Group type: EXPERIMENTAL
Intervention: Partially hydrogenated soybean oil-based stick margarine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Soybean oil
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 8
Study: 1571681

Group type: EXPERIMENTAL
Intervention: Home based care (daily living programme)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Standard hospital care
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Home based care
Number of subjects: 189
Study: 3899973

Group type: EXPERIMENTAL
Intervention: Benzydamine mouthwash
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30596272

Group type: EXPERIMENTAL
Intervention: Implementation intention intervention
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control
Number of subjects: 63
Study: 28866457

Group type: EXPERIMENTAL
Intervention: Cholangioscopy-guided laser lithotripsy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional therapy only
Number of subjects: 60
Study: 27108819

Group type: EXPERIMENTAL
Intervention: Benzydamine hydrochloride gel
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: 5% lidocaine hydrochloride gel
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: 10% lidocaine hydrochloride spray
Number of subjects: 124

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 124
Study: 24704135

Group type: EXPERIMENTAL
Intervention: Revised Contingent Voucher (RCV)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Usual Contingent Voucher (CV)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Non-Contingent Voucher (NCV)
Number of subjects: 118
Study: 21824050

Group type: EXPERIMENTAL
Intervention: Rituximab added to fludarabine and cyclophosphamide (R-FC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fludarabine and cyclophosphamide (FC)
Number of subjects: 0
Study: 19640357

Group type: EXPERIMENTAL
Intervention: Nelfabiovir (Bakhtar Bioshimi, Iran) 250 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Viracept (Roche, Germany) 250 mg
Number of subjects: 24
Study: 17461873

Group type: EXPERIMENTAL
Intervention: Intracoronary enalaprilat (50 microg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo/saline (PL)
Number of subjects: 22
Study: 15190828

Group type: EXPERIMENTAL
Intervention: nCPAP treatment from 22:00 to 6:00 per night for 1 month
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 27
Study: 11777513

Group type: EXPERIMENTAL
Intervention: Computer-assisted virtual urethral pressure profile
Number of subjects: 61
Study: 9821925

Group type: EXPERIMENTAL
Intervention: Ototopical antibiotics plus topical phenylephrine
Number of subjects: 208

Group type: COMPARATOR
Intervention: Ototopical antibiotics
Number of subjects: 208
Study: 9221158

Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg of moradole
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 1785268

Group type: EXPERIMENTAL
Intervention: Induction of labor (n = 139)
Number of subjects: 369

Group type: COMPARATOR
Intervention: Conservative management (n = 138)
Number of subjects: 369
Study: 6796322

Group type: EXPERIMENTAL
Intervention: Propranolol 20 mg orally four times daily for 5 days
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo four times daily for 5 days
Number of subjects: 9
Study: 31028447

Group type: EXPERIMENTAL
Intervention: Model with radiomic features combined with dosimetric parameters
Number of subjects: 94

Group type: COMPARATOR
Intervention: Radiomic features alone
Number of subjects: 94
Study: 28948326

Group type: EXPERIMENTAL
Intervention: Patient navigation intervention for elective surgery in the mountain group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group from mountainous area
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group from plains
Number of subjects: 0
Study: 23484369

Group type: EXPERIMENTAL
Intervention: Polaprezinc (zinc agent)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study: 22159931

Group type: EXPERIMENTAL
Intervention: Gabapentin 1,200 mg day-1
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg day-1
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 18579230

Group type: EXPERIMENTAL
Intervention: metoprolol+felodipine-placebo (MP group, n=23)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: metoprolol+felodipine (MF group, n=20)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: metoprolol-placebo+felodipine-placebo (PP group, n=20)
Number of subjects: 63
Study: 17956454

Group type: EXPERIMENTAL
Intervention: Insulin sensitivity measured by the euglycaemic clamp
Number of subjects: 818

Group type: EXPERIMENTAL
Intervention: HOMA‐IR
Number of subjects: 818

Group type: EXPERIMENTAL
Intervention: Fasting insulin
Number of subjects: 818

Group type: EXPERIMENTAL
Intervention: HOMA‐IR and fasting insulin
Number of subjects: 818

Group type: EXPERIMENTAL
Intervention: HOMA‐IR and insulin sensitivity measured with the euglycaemic clamp
Number of subjects: 818
Study: 15119916

Group type: EXPERIMENTAL
Intervention: Long-acting risperidone 25 mg
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Long-acting risperidone 50 mg
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Long-acting risperidone 75 mg
Number of subjects: 282

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 282
Study: 11340827

Group type: EXPERIMENTAL
Intervention: Preschool speech and language therapy services
Number of subjects: 68
Study: 9279482

Group type: EXPERIMENTAL
Intervention: Structured exercise and support programme
Number of subjects: 26

Group type: COMPARATOR
Intervention: Standard outpatient clinic education
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Increased activity over 6 months
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Increased activity over 12 months
Number of subjects: 26
Study: 7920892

Group type: EXPERIMENTAL
Intervention: Testosterone or GnRH treatment
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (normal men)
Number of subjects: 15
Study: 2823864

Group type: EXPERIMENTAL
Intervention: Extruded product
Number of subjects: 7

Group type: COMPARATOR
Intervention: Bran-gluten-starch mixture
Number of subjects: 7
Study: 29471466

Group type: EXPERIMENTAL
Intervention: 0.3 ppm ozone for 2 h during intermittent exercise
Number of subjects: 32

Group type: COMPARATOR
Intervention: Filtered air (FA)
Number of subjects: 32
Study: 28010832

Group type: EXPERIMENTAL
Intervention: Acupuncture at CV-12 (Zhongwan)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo control (sham point on the right side of the abdomen)
Number of subjects: 36
Study: 25193416

Group type: EXPERIMENTAL
Intervention: External fixation
Number of subjects: 110

Group type: COMPARATOR
Intervention: Volar locking plates
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: External fixation (patients aged <50 years)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 110
Study: 23174047

Group type: EXPERIMENTAL
Intervention: clindamycin 1%/BPO 5% gel
Number of subjects: 48

Group type: COMPARATOR
Intervention: adapalene 0.1%/BPO 2.5% gel
Number of subjects: 48
Study: 20158589

Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.03% ointment, applied twice weekly for 12 months
Number of subjects: 153

Group type: COMPARATOR
Intervention: Standard flare-only therapy
Number of subjects: 153
Study: 18544020

Group type: EXPERIMENTAL
Intervention: tgAAC09 at 3 x 10(9) DNase resistant particles (DRP) (n = 16)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: tgAAC09 at 3 x 10(10) DRP (n = 23)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: tgAAC09 at 3 x 10(11) DRP (n = 25)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (n = 16)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: tgAAC09 boost dose of 3 x 10(11) DRP
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: tgAAC09 (overall)
Number of subjects: 80
Study: 16174195

Group type: EXPERIMENTAL
Intervention: Interdisciplinary teamwork
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Leadership in interdisciplinary teams
Number of subjects: 0
Study: 12357317

Group type: EXPERIMENTAL
Intervention: T-fastener gastropexy
Number of subjects: 90

Group type: COMPARATOR
Intervention: No gastropexy
Number of subjects: 90
Study: 10521843

Group type: EXPERIMENTAL
Intervention: Comparative genomic hybridization (CGH) with DOP-PCR amplified DNA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal genomic DNA that underwent DOP-PCR
Number of subjects: 0
Study: 7537110

Group type: COMPARATOR
Intervention: Interleukin-6 (IL-6) administered at escalating doses from 0.5 to 10 micrograms/kg/d during chemotherapy cycles 2 to 6.
Number of subjects: 3

Group type: COMPARATOR
Intervention: Interleukin-6 (IL-6) administered before chemotherapy.
Number of subjects: 3

Group type: COMPARATOR
Intervention: Interleukin-6 (IL-6) administered during chemotherapy.
Number of subjects: 3

Group type: COMPARATOR
Intervention: Interleukin-6 (IL-6) administered after chemotherapy.
Number of subjects: 3

Group type: COMPARATOR
Intervention: Interleukin-6 (IL-6) administered at escalating doses up to 10 micrograms/kg/d.
Number of subjects: 3
Study: 1800252

Group type: EXPERIMENTAL
Intervention: Incontinence training program
Number of subjects: 166
Study: 7049582

Group type: EXPERIMENTAL
Intervention: Active treatment (hydrochlorothiazide plus triamterene, with the addition of methyldopa if necessary)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30836896

Group type: EXPERIMENTAL
Intervention: Culling of badgers for disease control
Number of subjects: 0
Study: 27553029

Group type: EXPERIMENTAL
Intervention: Winning the lottery ($100 cash grant)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (eligible non-winners)
Number of subjects: 0
Study: 26684265

Group type: EXPERIMENTAL
Intervention: Cycle ergometer training (PD-C)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Treadmill training (PD-T)
Number of subjects: 29
Study: 25351765

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Mosapride (M)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Mosapride & Sham Electro-acupuncture (MS)
Number of subjects: 243
Study: 22740305

Group type: EXPERIMENTAL
Intervention: 1.25 % povidone-iodine (PI) combined with 0.5 % topical levofloxacin (LVFX)
Number of subjects: 100

Group type: COMPARATOR
Intervention: 5 % povidone-iodine (PI)
Number of subjects: 100
Study: 19127161

Group type: EXPERIMENTAL
Intervention: Injection therapy (corticosteroids, local anesthetics, and other drugs)
Number of subjects: 1179

Group type: COMPARATOR
Intervention: Injection therapy
Number of subjects: 1179
Study: 18077809

Group type: EXPERIMENTAL
Intervention: Dexamethasone (16 mg twice daily for 4 days)
Number of subjects: 465

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: Intravenous ceftriaxone (2 g twice daily for 10 days)
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: Intramuscular ceftriaxone (2 g twice daily for 10 days)
Number of subjects: 465
Study: 15231553

Group type: EXPERIMENTAL
Intervention: Fluoxetine 10-60 mg/day
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 11181655

Group type: COMPARATOR
Intervention: CMF plus placebo
Number of subjects: 2008

Group type: EXPERIMENTAL
Intervention: CMF plus TAM
Number of subjects: 2008

Group type: COMPARATOR
Intervention: AC plus placebo
Number of subjects: 2008

Group type: EXPERIMENTAL
Intervention: AC plus TAM
Number of subjects: 2008
Study: 9702843

Group type: EXPERIMENTAL
Intervention: Intravenous itraconazole (200 mg as a 1-hour infusion twice daily for 2 days, then 200 mg once daily for 5 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Itraconazole capsules (200 mg once daily for 28 days)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Itraconazole capsules (200 mg twice daily for 28 days)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intravenous itraconazole followed by itraconazole capsules twice daily
Number of subjects: 30
Study: 7986124

Group type: EXPERIMENTAL
Intervention: Frequency-doubled Q-switched Nd: YAG laser (532 nm, 2.0-mm spot size, 10 nanoseconds) at fluences of 2, 3, 4, or 5 J/cm2
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Frequency-doubled Q-switched Nd: YAG laser (532 nm)
Number of subjects: 49
Study: 3202422

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT) with a pressure threshold breathing device at 30% of maximal inspiratory pressure (Plmax)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Inspiratory muscle training (IMT) with a pressure threshold breathing device at 15% of maximal inspiratory pressure (Plmax)
Number of subjects: 22
Study: 30885281

Group type: EXPERIMENTAL
Intervention: Endoscopic assisted coblation adenoidectomy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional cold curettage adenoidectomy
Number of subjects: 60
Study: 28693439

Group type: EXPERIMENTAL
Intervention: Tapentadol
Number of subjects: 266

Group type: COMPARATOR
Intervention: Oxycodone/naloxone
Number of subjects: 266
Study: 25947187

Group type: EXPERIMENTAL
Intervention: Integrated internet addiction prevention program
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 56
Study: 24115820

Group type: EXPERIMENTAL
Intervention: Grasper type scissors (GTS)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Hook knife plus coagrasper (HKC)
Number of subjects: 76
Study: 21454978

Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthwash for 2 weeks (Group A)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Probiotic yogurt containing Lactobacillus rhamnosus GG (LGG) for 3 weeks (Group B)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Chlorhexidine followed by probiotic yogurt (Group C)
Number of subjects: 105
Study: 18093113

Group type: EXPERIMENTAL
Intervention: Familiar identities (parents, teachers)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Unfamiliar identities (strangers)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Dynamic expressions of five emotions (happy, sad, anger, fear, disgust)
Number of subjects: 153
Study: 16564254

Group type: EXPERIMENTAL
Intervention: L-arginine (7.5 g in 500 mL of cardioplegic solution)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control (group B)
Number of subjects: 65